Accord Healthcare

Accord Healthcare is a rapidly growing pharmaceutical company headquartered in the United Kingdom, with a significant presence across Europe and globally. Specializing in generic and biosimilar medicines, Accord Healthcare operates in over 80 countries, delivering affordable and vital medicines to national health systems. The company’s core mission centers on patient-centricity, aiming to improve patient outcomes by working closely with patient groups and advocates to understand their needs and develop healthcare solutions accordingly. This collaborative approach is grounded in transparency, trust, and compliance, ensuring that partnerships with patient organizations are equitable and free from conflicts of interest.

Accord Healthcare’s strategic focus includes securing valuable patient insights throughout the medicine development process, supporting system recovery, promoting shared decision-making, and addressing health inequalities. The company maintains strong ethical standards in its interactions with stakeholders and emphasizes open dialogue to foster innovation and accessibility in healthcare.

In the EU context, Accord Healthcare actively supports policy initiatives such as the EU Critical Medicines Act, advocating for measures to ensure supply security and access to essential generic medicines. The company aligns itself with industry groups like Medicines for Europe and EFPIA to advance these goals. With a workforce of around 2,000 employees across the EMENA region and operations in all 27 EU member states, Accord Healthcare is a significant player in European pharmaceutical lobbying and policy engagement.

Their lobbying efforts focus on promoting policies that enhance the availability and affordability of generic and biosimilar medicines, supporting regulatory frameworks that facilitate market access, and contributing to the EU’s healthcare resilience and sustainability. Accord Healthcare’s transparency policies and adherence to EU lobbying regulations underscore its commitment to ethical advocacy and responsible corporate citizenship.

Headquarters: United Kingdom
Industry: Pharmaceutical (Generic and Biosimilar Medicines)
Operations: Over 80 countries globally, including all 27 EU member states
Employees: Approximately 2,000 in EMENA region
Core Focus: Patient-centric healthcare solutions, generic and biosimilar medicines access, policy advocacy for medicine supply security
Affiliations: Medicines for Europe, EFPIA

No related lobbyists found.

Pharmaceutical lobbying
Generic and biosimilar medicines policy
Patient advocacy and engagement
Healthcare access and affordability
Regulatory affairs and compliance
EU healthcare policy and supply security

Accord Healthcare networks with several key organizations and industry groups, including:

Medicines for Europe: Collaborates on EU policy initiatives like the Critical Medicines Act to secure medicine supply and access.
EFPIA (European Federation of Pharmaceutical Industries and Associations): Aligns with EFPIA guidance for transparency and lobbying practices.
Patient Advocacy Groups: Partners with various patient organizations to incorporate patient insights into healthcare strategies.
European Commission and other EU institutions: Engages in dialogue and meetings to influence pharmaceutical policy and regulation.

Exact financial data on lobbying expenditures by Accord Healthcare since registration with the EU Transparency Register is not explicitly available in the provided sources. Typically, pharmaceutical companies report their lobbying costs in the range of several hundred thousand to a few million euros annually, depending on the scale of their activities.

Accord Healthcare engages with multiple EU structures, including:

European Commission (DG SANTE and other relevant Directorates-General)
European Parliament (health and pharmaceutical committees)
Patient advocacy forums supported by the EU
Industry associations such as EFPIA and Medicines for Europe

Specific records of meetings held by Accord Healthcare with EU institutions since registration are not detailed in the available information. However, the company regularly participates in consultations, advisory boards, and policy discussions related to pharmaceutical legislation and healthcare access.